COVID-19 lockdown linked to fall in early childhood vaccination in England, a rise in Scotland news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Biological E India s next Serum, Bharat Biotech of COVID-19 vaccine
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.
PB Jayakumar | June 2, 2021 | Updated 23:07 IST
Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India.
The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccine manufacturing following its latest deal with Canada-based biotech company Providence Therapeutics.
In addition to the Providence deal, Biological E currently has a couple of in-house COVID-19 vaccines under development and another major manufacturing contract agreement for Johnson & Johnson s single-dose COVID-19 vaccine. It was among the earliest Indian companies to tap potential COVID-19 vaccine opportunities.
THIS article follows on from my original piece in
The Conservative Woman last week which discussed a large number of concerns which I have with the precipitous UK rollout of the Pfizer vaccine. This follow-up stands on its own, but is best read after the first article.
Pfizer have no idea if the vaccine can prevent symptoms or transmission
I wrote in my original article that ‘the trials for this vaccine . . . were not designed to test if the vaccine can reduce severe COVID-19 symptoms, ie hospital admissions ICU admission or death. The trials were also not designed to test if the vaccine can interrupt transmission.’